Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.49 |
| ▸ | HRH2 | P25021 | 4/20 | 0.49 |
| ▸ | HRH1 | P35367 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13552419 | 1.00 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL12717290 | 1.00 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL12717292 | 0.89 | HTR1A (0.58) | HRH3HRH2HRH1HTR1A | |
| SCHEMBL20698407 | 0.89 | HTR1A (0.58) | HRH3HRH2HRH1HTR1A | |
| SCHEMBL14419811 | 0.89 | HTR1A (0.58) | HRH3HRH2HRH1HTR1A | |
| SCHEMBL9921273 | 0.89 | LTA4H (0.47) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL16418018 | 0.89 | LTA4H (0.47) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL12717293 | 0.89 | HRH3 (0.47) | HRH3HRH2HRH1ACHESLC6A4 | |
| SCHEMBL5949496 | 0.89 | LTA4H (0.47) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL20698402 | 0.84 | GBA1 (0.44) | HRH3HRH2HRH1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3664793-B1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3658522-B1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11059834-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2020047035-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20200055869-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2019032547-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019023575-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9149463-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-06-04 | — | — | US | disclosed |
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059834-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH2 158/4885HRH1 234/4885 |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885HRH2 4404/4885HRH1 4601/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885HRH2 4404/4885HRH1 4601/4885 |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885HRH2 4404/4885HRH1 4601/4885 |
| US-20200055869-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH2 158/4885HRH1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.